Kellie Zeichner, BSN, RN, OCN

Kellie Zeichner BSN, RN, OCN, explains how her institution created a standardized monitoring procedure for insulinoma care.

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.